Epilepsy Center, Neurocenter, Kuopio University Hospital and Faculty of Health Sciences, School of Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland
-
-
Paper of the MonthFeatured SliderPaper of the month: No benefit from solanezumab in Alzheimer disease
by Elena Moro For March 2018, we have selected: Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med 2018;378:321-330. Alzheimer’s disease (AD) pathology can be related to either excessive production or reduced elimination of beta amyloid (Aβ), which eventually results in oligomers, fibrils, and neuritic Aβ plaques. -
InterviewsResearchScientific CornerTop ArticlesRare Disease Day: Interview with Holm Graessner, Coordinator Rare Neurologic Diseases European Reference Network
Antonio Federico (AF): On January 29-30, there has been in Tubingen the Kick-Off Meeting of the EU Project Solve-RD. You and Prof. Olaf Riess are coordinating this project. Can you summarize the aim and the activities of this important project? Holm Graessner (HG): To obtain a molecularly confirmed diagnosis remains one of the largest challenges for rare disease patients. To jointly tackle this challenge a core group of four European Reference Networks including the European Reference Network for Rare Neurological Diseases has motivated, designed and put together the Solve-RD project which is the first ERN based H2020 funded research project. Solve-RD brings together 21 partners from 10 countries which will be running from 2018 to 2022. -
ResearchScientific CornerTop Articles
Rare Disease Day: Update from the Scientific Panel on Sleep-wake Disorders
Scientific news: Narcolepsy Currently the most discussed topic in narcolepsy research is the auto-immune hypothesis. Both animal and human studies have provided clues, but still no definite evidence regarding the auto-immune etiology of narcolepsy. Recent findings point towards T-cell related… Continue Reading -
ResearchScientific CornerTop ArticlesRare Disease Day: 2nd Teaching Course of the EAN Task Force for Rare Neurologic Diseases
It is our great pleasure to announce the 2nd edition of the EAN Task Force for Rare Neurologic Diseases Teaching Course, to be organized in Cluj-Napoca (Romania), from 5-7 September 2018. As last year’s event was a success, the Task… Continue Reading -
ResearchScientific panels reports
Activities of the EAN Scientific Panel Muscle and NMJ disorders 2016/2017
Chairs Prof. A. Toscano, Messina, Italy & Prof. B. Schoser, Munich, Germany with 24 attendees from 14 countries. Topic 1: Guidelines Antonio Toscano and Benedikt Schoser gave a short overview on the EAN principles of a guideline production and… Continue Reading -
In Nature Reviews Neurology (Multiple system atrophy: insights into a rare and debilitating movement disorder, 13;232-243; 2017), Florian Krismer and Gregor Wenning from Innsbruck University Hospital provide a comprehensive overview of Multiple System Atrophy (MSA) linking the current state… Continue Reading
-
For February 2018, we have selected: Feneberg E, Oeckl P, Steinacker P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology 2018;90:e22-30. doi:10.1212/WNL.0000000000004761. Amyotrophic lateral sclerosis (ALS) is a devastating neurological disorder affecting motor neurons. The course of the disease is progressive with life span of 3 to 5 years from the onset of the symptoms. -
The EAN Scientific Panel Neurogenetics met during the recent EAN congress in Amsterdam. Co-chairs Thomas Klopstock from Germany and Jean-Marc Burgunder from Switzerland welcomed the participants, with a special greeting of representatives from EFNA (Cathalijne van Doorne, vice president) and… Continue Reading
-
For January 2018, we have selected: Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. NEJM 2017;377:1713-1722. Spinal muscular atrophy (SMA) is caused by loss or dysfunction of the gene encoding survival motor neuron 1 protein (SMN1). Disease severity is also influenced by a second gene, SMN2, which can produce smaller amounts of this protein. -
Highliths of 2017: I. 7th European Teaching Course on Neurorehabilitation | RoNeuro Brain Days This event is organized by the Foundation of the Society for the Study of Neuroprotection and Neuroplasticity, together with the Romanian Society of Neurology and… Continue Reading
-
ResearchScientific panels reportsActivities of the EAN Scientific Panel Higher Cortical Functions 2016/2017
The EAN Scientific Panel held its annual meeting on 25 June 2017 09:45 to 10:45 during the 3rd EAN Congress in Amsterdam. Chair of the meeting: Lueder Deecke, Management Group members present: Co-Chair Stefano Cappa, Pasquale Calabrese, Wolfgang Heide,… Continue Reading -
ResearchScientific panels reports
Activities of the EAN Scientific Panel Neuroepidemiology 2016-2017
SP Neuroepidemiology met during recent EAN Congress in Amsterdam. Co-chairs Ettore Beghi and Maura Pugliatti from Italy welcomed members and introduced Dafin Muresanu from Romania, as a new liaison officer between the scientific committee and scientific panel. Co-chairs reported… Continue Reading -
A business meeting of the EAN Specialty Panel of Neurotoxicology was held during the 3rd EAN Congress in Amsterdam. Nine participants attended the meeting, of which panel members: Maurizio Leone – Italy, Albert Ludolph – Germany, Geir Bråthen –… Continue Reading
-
Please find below articles from French authors and co-authors that were published in the European Journal of Neurology